Cheap and healthy — worth a proper look.

The math shows a margin of safety, and nothing is obviously deteriorating.

Price $429.69 taken 2026-11-15 · market cap about $97B
Fair value $593 range $446 to $817 · from the FY25 annual report
Margin of safety +38%, below fair value a margin of safety · the price sits below fair value

The five checks

3 good · 1 caution · 1 warning

  • Good
    Undervalued
    Fair value ~$593 vs $430 — a margin of safety of 38%.
  • Warning
    Price assumes a big acceleration
    You'd need ~1%/yr free-cash-flow growth to justify today's price; it has done -24.1%/yr lately.
  • Good
    Revenue still growing
    Up 12.5% last year — demand isn't the problem.
  • Caution
    Cash flow flat-to-down
    Free cash flow ~-24.1%/yr — big, but not compounding. The crux for a value buyer.
  • Good
    Fortress balance sheet
    Net cash positive (+$4B) — little solvency risk.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $430 to make sense?

The price needs ~1% a year
Elevance Health has delivered -24.1% a year over the last three years

Price assumes a big acceleration.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, typical yearThe five-year norm, from the annual reports$6.8B
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$55.4B
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $73.3B
  4. The business, in today's money$128.7B
  5. Add net cashCash and securities less borrowings and finance leases+ $4.5B
  6. Divide by the shares on file÷ 0.2246B

Fair value per share$593

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $446 to $817 range comes from.

3% growth5% growth7% growth
8% discount$603$702$817
9% discount$513$593$686
10% discount$446$513$591

The blue cell is the published method. Every cell sits above today’s price.

Free cash flow, ten years

$ billions · Form 10-K

$2.7B FY16 $3.4B FY17 $2.6B FY18 $5.0B FY19 $9.7B FY20 $7.3B FY21 $7.3B FY22 $6.8B FY23 $4.5B FY24 $3.2B FY25
  1. FY25 $3.2B
  2. FY24 $4.5B
  3. FY23 $6.8B
  4. FY22 $7.3B
  5. FY21 $7.3B
  6. FY20 $9.7B
  7. FY19 $5.0B
  8. FY18 $2.6B
  9. FY17 $3.4B
  10. FY16 $2.7B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Elevance Health, Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Fair value is based on typical free cash flow over the last five years ($6.8B), not the latest year ($3.2B), which sat 53% below the company's own norm. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $429.69 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Elevance Health another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →